Vaccine against Chikungunya in making
June 10, 2023
  • Circulation
  • Advertise
  • Careers
  • About Us
  • Contact Us
Organiser
  • ‌
  • Bharat
  • World
  • G20
  • Editorial
  • Analysis
  • Opinion
  • Sports
  • More
    • Defence
    • RSS in News
    • Azadi Ka Amrit Mahotsav
    • My States
    • Vocal4Local
    • Business
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
    • Podcast
SUBSCRIBE
No Result
View All Result
  • ‌
  • Bharat
  • World
  • G20
  • Editorial
  • Analysis
  • Opinion
  • Sports
  • More
    • Defence
    • RSS in News
    • Azadi Ka Amrit Mahotsav
    • My States
    • Vocal4Local
    • Business
    • Special Report
    • Culture
    • Sci & Tech
    • Entertainment
    • Education
    • Books
    • Interviews
    • Travel
    • Health
    • Obituary
    • Podcast
No Result
View All Result
Organiser
No Result
View All Result
  • Home
  • Bharat
  • World
  • G20
  • Editorial
  • Opinion
  • Analysis
  • Culture
  • Defence
  • RSS in News
  • My States
  • Vocal4Local
  • Subscribe
Home Bharat

Vaccine against Chikungunya in making

WEB DESK by WEB DESK
Aug 27, 2021, 12:00 am IST
in Bharat
Share on FacebookShare on TwitterTelegramEmail

                                                                                                                                                                                                                   
New Delhi: A new weapon against the debilitating infection of Chikungunya could soon be in the offing. A multi-country Phase II/III clinical trial of a vaccine led by the International Vaccine Institute (IVI) in partnership with Bharat Biotech International Ltd (BBIL) began in Costa Rica on Tuesday. It is funded by the Coalition for Epidemic Preparedness Innovations (CEPI) with support from the Ind-CEPI mission of the Department of Biotechnology (DBT), India.

IVI is advancing the vaccine's clinical development named BBV87 through Phase II/III randomized, controlled trial to evaluate the safety and immunogenicity of a 2-dose regimen in healthy adults at nine clinical trial sites across five countries with endemic Chikungunya.

The Global Chikungunya vaccine Clinical Development Programme (GCCDP) seeks to develop and manufacture an affordable Chikungunya vaccine to achieve WHO prequalification to enable its distribution in low- and middle-income countries, consistent with CEPI’s core commitment to equitable access, affordability, and sustainability.

As needed, CEPI or Bharat Biotech International Ltd may propose a third-party for manufacturing of a stockpile of the investigational product to be used for further clinical trials in outbreak conditions to advance vaccine development, or under an emergency use authorization in emergencies, based on national or international guidance (such as by the WHO).

Dr. Krishna Ella, Chairman and Managing Director of Bharat Biotech, said: “The vaccine candidate is an ingenious, well-researched vaccine. The human trial has begun an important trial phase in furthering the evaluation of safety and immunogenicity.”

Dr. Sushant Sahastrabuddhe, acting Associate Director-General at IVI and Principal Investigator of GCCDP, said: “The start of this trial in Costa Rica is a significant milestone in the effort to make available a safe, effective, and affordable Chikungunya vaccine for the one billion people around the world at risk of Chikungunya virus infection.”

The launch of the trial furthers CEPI’s US dollars 3.5billion plan, launched in March 2021, to tackle future epidemics and pandemics. CEPI first partnered with IVI and BBIL in June 2020, providing up to US dollars 14.1 million for vaccine manufacturing and clinical development of the BBV87 vaccine candidate.

The funding is supported by the European Union’s (EU’s) Horizon 2020 programme. The consortium was also supported with a grant of up to US dollar 2.0 million from the Indian Government’s Ind-CEPI initiative to fund the set-up of GMP manufacturing facilities for the vaccine in India and subsequent manufacture of clinical trial materials.

“It is very encouraging to witness the commencement of Phase II/III study of BBV87 in Costa Rica. This milestone is a first step towards developing a promising vaccine candidate against Chikungunya, an exhausting disease,” said Dr. Renu Swarup, Secretary, DBT.

BBV87 vaccine is an inactivated whole virion vaccine based on a strain derived from an East, Central, South African (ECSA) genotype.

 

Inactivated virions technology has a safety profile that potentially makes this vaccine accessible to special populations, such as the immunocompromised and pregnant women, that some other technologies cannot reach.

Courtesy: India Science Wire

ShareTweetSendShareSend
Previous News

Kyuili: The Military Strategist of Velu

Next News

Dheeran Chinnamalai: A Warrior who laid down his life for sovereignty of kongu soil

Related News

Malady of Minoritism

Malady of Minoritism

Auto Draft

India, New Zealand hold first Round Table Joint Meeting for ‘enhanced economic relations’ in Delhi: Read Details

Study discovers cells linking chronic psychological stress to inflammatory bowel disease

Study discovers cells linking chronic psychological stress to inflammatory bowel disease

Auto Draft

Indo-Canadian MP demands action on celebration of Indira Gandhi’s assassination; says new low for Khalistan supporters

Akhand Bharat Map in the New Parliament is a cultural, historical one, not political: Nepal’s PM Prachanda

Akhand Bharat Map in the New Parliament is a cultural, historical one, not political: Nepal’s PM Prachanda

Uttar Pradesh: Shahid barged into minor’s house, raped and hammered her to death; hangs her body before fleeing

Uttar Pradesh: Shahid barged into minor’s house, raped and hammered her to death; hangs her body before fleeing

Comments

The comments posted here/below/in the given space are not on behalf of Organiser. The person posting the comment will be in sole ownership of its responsibility. According to the central government's IT rules, obscene or offensive statement made against a person, religion, community or nation is a punishable offense, and legal action would be taken against people who indulge in such activities.

Latest News

Malady of Minoritism

Malady of Minoritism

Auto Draft

India, New Zealand hold first Round Table Joint Meeting for ‘enhanced economic relations’ in Delhi: Read Details

Study discovers cells linking chronic psychological stress to inflammatory bowel disease

Study discovers cells linking chronic psychological stress to inflammatory bowel disease

Auto Draft

Indo-Canadian MP demands action on celebration of Indira Gandhi’s assassination; says new low for Khalistan supporters

Akhand Bharat Map in the New Parliament is a cultural, historical one, not political: Nepal’s PM Prachanda

Akhand Bharat Map in the New Parliament is a cultural, historical one, not political: Nepal’s PM Prachanda

Uttar Pradesh: Shahid barged into minor’s house, raped and hammered her to death; hangs her body before fleeing

Uttar Pradesh: Shahid barged into minor’s house, raped and hammered her to death; hangs her body before fleeing

RSS founder Dr Hedgewar & his contribution to the freedom struggle

RSS founder Dr Hedgewar & his contribution to the freedom struggle

Love Jihad: Here is a list of 60 incidents where Hindu women have been killed by their Muslim partners

Love Jihad: Here is a list of 60 incidents where Hindu women have been killed by their Muslim partners

India is recognised as a responsible development partner and voice of the Global South: President Droupadi Murmu

India is recognised as a responsible development partner and voice of the Global South: President Droupadi Murmu

Indian Catholic Church Sex Scandal: Priest exploiting Nuns and Hindu women exposed

Indian Catholic Church Sex Scandal: Priest exploiting Nuns and Hindu women exposed

  • Privacy
  • Terms
  • Cookie Policy
  • Refund and Cancellation
  • Delivery and Shipping

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies

No Result
View All Result
  • Home
  • Bharat
  • World
  • Editorial
  • Analysis
  • Opinion
  • Defence
  • Culture
  • Sports
  • Business
  • RSS in News
  • My States
  • Vocal4Local
  • Special Report
  • Sci & Tech
  • Entertainment
  • Education
  • Books
  • Interviews
  • Travel
  • Health
  • Obituary
  • Podcast
  • Subscribe
  • Advertise
  • Circulation
  • Careers
  • About Us
  • Contact Us
  • Privacy Policy
  • Cookie Policy
  • Terms of Use
  • Refund and Cancellation

© Bharat Prakashan (Delhi) Limited.
Tech-enabled by Ananthapuri Technologies